Search research articles
Contact Us
Filters
Showing results (131-140 of 145) with videos related to
Page
of 15
Sort By:
The Lancet. Gastroenterology & Hepatology
|
September 9, 2019
Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study
Marja-Leena Lähdeaho, Mika Scheinin, Pekka Vuotikka, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
March 22, 2003
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier
Oskar T Johannsson, Synnöve Staff, Johan Vallon-Christersson, et al.
The Lancet. Gastroenterology & Hepatology
|
March 10, 2023
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Jason A Tye-Din, A James M Daveson, Gautam Goel, et al.
Nature Immunology
|
June 24, 2024
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease
Valeriia Dotsenko, Bernhard Tewes, Martin Hils, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 25, 2007
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H Saal, Peter Johansson, Karolina Holm, et al.
The Lancet. Gastroenterology & Hepatology
|
November 9, 2024
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
A James M Daveson, Richard Stubbs, Thomas M Polasek, et al.
BMC Cancer
|
August 4, 2016
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Qing-Bai She, Sofia K Gruvberger-Saal, Matthew Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
Heikki Joensuu, Petri Bono, Vesa Kataja, et al.
The Lancet. Oncology
|
September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Food & Function
|
January 14, 2022
Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control <i>in vivo</i> study
Angelo Andriulli, Antonio Bevilacqua, Orazio Palmieri, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 145) with videos related to
Sort By:
Page
of 15
The Lancet. Gastroenterology & Hepatology
|
September 9, 2019
Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study
Marja-Leena Lähdeaho, Mika Scheinin, Pekka Vuotikka, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
March 22, 2003
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier
Oskar T Johannsson, Synnöve Staff, Johan Vallon-Christersson, et al.
The Lancet. Gastroenterology & Hepatology
|
March 10, 2023
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Jason A Tye-Din, A James M Daveson, Gautam Goel, et al.
Nature Immunology
|
June 24, 2024
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease
Valeriia Dotsenko, Bernhard Tewes, Martin Hils, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 25, 2007
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H Saal, Peter Johansson, Karolina Holm, et al.
The Lancet. Gastroenterology & Hepatology
|
November 9, 2024
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
A James M Daveson, Richard Stubbs, Thomas M Polasek, et al.
BMC Cancer
|
August 4, 2016
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Qing-Bai She, Sofia K Gruvberger-Saal, Matthew Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
Heikki Joensuu, Petri Bono, Vesa Kataja, et al.
The Lancet. Oncology
|
September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Food & Function
|
January 14, 2022
Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control <i>in vivo</i> study
Angelo Andriulli, Antonio Bevilacqua, Orazio Palmieri, et al.
Page
of 15